Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer

JNCI Cancer Spectrum
Jahan J MohiuddinRonald C Chen

Abstract

Neoadjuvant chemotherapy in breast cancer reduced mastectomy rates by 7% to 13% in randomized trials. However, the differential effects for women with different stages, receptor subtypes, and ages are unknown. We compared mastectomy rates in women who did vs did not receive neoadjuvant chemotherapy in 18 patient subgroups. The main objective was to quantify the potential benefit from neoadjuvant chemotherapy in reducing mastectomy rates for each subgroup. Our retrospective analysis used data from the National Cancer Data Base, which includes approximately 70% of incident cancers across the United States. Absolute risk reductions for mastectomy were determined for 18 subgroups of clinical stage, receptor subtype, and age group. In each subgroup, propensity score weighting balanced measured covariates between women treated with vs without neoadjuvant chemotherapy. A total of 55 709 patients were analyzed. In clinical stage IIA disease, only patients with human epidermal growth factor receptor 2 (HER2)-positive tumors had reduced mastectomy rates associated with neoadjuvant chemotherapy (age < 60 years, 12%; age ≥ 60 years, 12.6%). For stage IIB cancers, neoadjuvant chemotherapy was associated with an absolute reduction in mastect...Continue Reading

References

Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherN V Dimitrov
Dec 23, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MakrisH T Ford
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A van der HageL Duchateau
Oct 22, 2003·Epidemiology·Tosiya Sato, Yutaka Matsuyama
Feb 18, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R WrightTim J Whelan
Mar 11, 2006·Pharmacoepidemiology and Drug Safety·Til StürmerRobert J Glynn
Jan 10, 2008·Annals of Surgical Oncology·Karl Y BilimoriaClifford Y Ko
Apr 15, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·William J GradisharRashmi Kumar

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.